4 ms·
This sounds awesome. How might it complement the "visual paired comparison" task of Zola et al. (2013) -- which has been commercialized by Neurotrack -- in help
by helloworld 9y ago
This sounds awesome. How might it complement the "visual paired comparison" task of Zola et al. (2013) -- which has been commercialized by Neurotrack -- in helping to identify those at risk of dementia?
Zola, S.M., Manzanares, C.M, Clopton, P., Lah, J.J., and Levey, A.I. (2013). Am J Alzheimers Dis Other Demen. 28(2): 179–184.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670591/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670591/
- Padideh 9y agoThere are many tests to tell you the risk of developing dementia, which is only a "probability" number. Darmiyan's brain maps show (and measure) the actual pathology (neurodegeneration) in the brain, at microscopic resolution. There is currently no other method to detect and quantify micro-structural abnormality in the brain at presymptomatic stages of dementia, which is one of the main reasons why all clinical trials of Alzheimer's test drugs keep failing, one after another.